Evaluation of direct medical costs of hospitalization for febrile neutropenia

Cancer

Volumn 116, Issue 3, 2010, Pages 742-748

  Lathia, Nina ^a,b   Mittmann, Nicole ^b,c   DeAngelis, Carlo ^a,b   Knowles, Sandra ^b   Cheung, Matthew ^b   Piliotis, Eugenia ^b   Shear, Neil ^b   Walker, Scott ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Costs and cost analysis; Economics; Fever; Neoplasms; Neutropenia

Indexed keywords

ANTIFUNGAL AGENT; CEFALEXIN; CEFAZOLIN; CIPROFLOXACIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANADA; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE UTILIZATION; HEMATOLOGIC MALIGNANCY; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; FEMALE; FEVER; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, ECONOMIC; NEUTROPENIA; RISK FACTORS;

EID: 76249099525     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24773     Document Type: Article

References (20)

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228-237.
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64:328-340.
4. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol. 1998;102:879-888.
5. National Cancer Institute of Canada. Comparison of Cancer in Canada from 1987 to 1997. Available at: www.incc.cancer.ca/ncic/internet/standard/0,3621, 84658243-85787780-91036744-langId-en,00.html Accessed September 28, 2007.
6. Canadian Cancer Society. Canadian Cancer Statistics 2007. Available at: www.cancer.ca/vgn/images/portal/cit-86751114/36/15/1816216925cw-2007stats-en. pdf Accessed September 24, 2007.
7. Dranitsaris G, Tran TM. Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer. 1995;31A:2174-2180.
8. Dranitsaris G, Tran TM, McGeer A, Narine L. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics. 1995;7:49-62.
9. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Care Cancer. 1997;5:489-499.
10. Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Pharmacoeconomics. 1997;11:566-577.
11. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
12. Bank of Canada. Inflation Calculator. Available at: http://www. bankofcanada.ca/en/rates/inflation-calc.html Accessed November 22, 2007.
13. Ontario Case Costing Initiative. Cost Analysis Tool. Available at: www.occp.com Accessed November 22, 2007.
14. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266.
15. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129-4134.
16. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003;89:43-49.
17. Cherif H, Johansson E, Bjorkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91:215-222.
18. Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics. 2003;21:1295-1313.
19. Cornish W, ed. Antimicrobial Handbook 2007-8. Toronto, Ontario: Sunnybrook Health Sciences Centre; 2007.
20. Ontario Ministry of Health and Longterm Care. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Available at: www.health.gov.on.ca/ english/providers/program/ohip/sob/sob-mn.html Accessed November 14, 2007.